Intranasal insulin for prevention of type 1 diabetes in children carrying increased HLA-conferred genetic risk

Trial Profile

Intranasal insulin for prevention of type 1 diabetes in children carrying increased HLA-conferred genetic risk

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DIPP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Sep 2008 Status changed from recruiting to discontinued
    • 23 Sep 2008 Primary endpoint 'Disease occurrence' has not been met. Results published in The Lancet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top